In a phase I clinical trial involving 10 patients with metastatic melanoma who were refractory to anti-PD-1 therapy, 3 of them were proved to convert to responders to PD-1 blockade again after FMT, and none of them had severe irAEs [18]. The gene discussed is PDCD1; the disease is metastatic melanoma.